Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as soblidotin and gemcitabine, use different ways
to stop tumor cells from dividing so they stop growing or die. Combining more than one drug
may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of soblidotin and
gemcitabine in treating patients with locally advanced or metastatic solid tumors.